Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis

AB Foundation

Status and phase: Completed; Phase 2; Phase 1

Conditions: Leishmaniasis

Treatments: Drug: miltefosine: 2.5 mg/kg/day for 42 days

Study type: Interventional

Funder types: Other

Identifiers

NCT00373568

05--01

Details and patient eligibility

About

Miltefosine (longer course) will be used to try to improve the cure rate of mucosal leishmaniasis

Full description

Miltefosine (42 days) will be used to try to improve upon the cure rate with 28 days of drug for bolivian mucosal leishmaniasisi

Sex: All

Ages: 12 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mucosal leishmaniasis

Exclusion criteria

• No comcomitant disease as judged by laboratory and clinical parameters

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)